Anti-VEGF Market by Type (VEGF-A Inhibitors, VEGF-B Inhibitors, VEGF-C Inhibitors and Placenta Growth Factor Inhibitors)
Industry: Healthcare
Published Date: April-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 422
Report ID: PMRREP33422
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Regulatory Landscape
4.2. Pipeline Assessment
4.3. Product Adoption and Usage Analysis
4.4. Key Marketing & Promotional Strategies Adopted by Companies
4.5. PESTLE Analysis
4.6. Porters Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Oncology Therapeutic Medicines Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in R&D Funding and Grants
5.2.2. Rising Research Activities for Rare Disease Indications
5.2.3. High Demand for Biologics
5.2.4. Surge in Research Collaborations for Development of Drugs
5.2.5. High Prevalence of Cancer
5.2.6. New Product Launch
5.2.7. Regulatory Approvals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug Types
6.1.2. Revenue By Types
6.1.3. Revenue By Disease Indication
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012–2022 and Forecast, 2023–2033
7.1. Historical Market Value (US$ Mn) Analysis, 2012–2022
7.2. Current and Future Market Value (US$ Mn) Projections, 2023–2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Drug Types
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Drug Types, 2012–2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Types, 2023–2033
8.3.1. Small Molecules
8.3.1.1. Pazopanib
8.3.1.2. Sunitinib
8.3.1.3. Regorafenib
8.3.1.4. Cabozantinib
8.3.1.5. Lenvatinib
8.3.1.6. Ponatinib
8.3.1.7. Cabozantinib
8.3.1.8. Axitinib
8.3.1.9. Tivozanib
8.3.1.10. Vandetanib
8.3.1.11. Sorafenib
8.3.1.12. Anlotinib
8.3.1.13. Apatinib
8.3.1.14. Fruquintinib
8.3.1.15. Surufatinib
8.3.2. Biologics
8.3.2.1. Bevacizumab
8.3.2.2. Ziv-Aflibercept
8.3.2.3. Ramucirumab
8.3.2.4. Ranibizumab
8.4. Market Attractiveness Analysis By Drug Types
9. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Types
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Types, 2012–2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types, 2023–2033
9.3.1. VEGF A Inhibitors
9.3.2. VEGF B Inhibitors
9.3.3. VEGF C Inhibitors
9.3.4. Placenta Growth Factor Inhibitors
9.4. Market Attractiveness Analysis By Types
10. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Disease Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2012–2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2023–2033
10.3.1. Oncology
10.3.1.1. Cervical Cancer
10.3.1.2. Non-Small Cell Lung Cancer
10.3.1.3. Renal Cell Carcinoma
10.3.1.4. Soft Tissue Sarcoma
10.3.1.5. Colorectal Cancer
10.3.1.6. Liver Cancer
10.3.1.7. Others
10.3.2. Hematology Disorders
10.3.3. Ophthalmology Disorders
10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
10.3.3.2. Diabetic Retinopathy
10.3.3.3. Others
10.4. Market Attractiveness Analysis By Disease Indication
11. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2012–2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023–2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Cancer Research Centers
11.3.4. Mail Order Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2012–2022 and Forecast 2023–2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2022
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023–2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2012–2022 and Forecast 2023–2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug Types
13.3.3. By Types
13.3.4. By Disease Indication
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Types
13.4.3. By Types
13.4.4. By Disease Indication
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug Types
13.8.1.2.2. By Types
13.8.1.2.3. By Disease Indication
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug Types
13.8.2.2.2. By Types
13.8.2.2.3. By Disease Indication
13.8.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2012–2022 and Forecast 2023–2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Types
14.3.3. By Types
14.3.4. By Disease Indication
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Types
14.4.3. By Types
14.4.4. By Disease Indication
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug Types
14.8.1.2.2. By Types
14.8.1.2.3. By Disease Indication
14.8.1.2.4. By Distribution Channel
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug Types
14.8.2.2.2. By Types
14.8.2.2.3. By Disease Indication
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug Types
14.8.3.2.2. By Types
14.8.3.2.3. By Disease Indication
14.8.3.2.4. By Distribution Channel
15. Europe Market Analysis 2012–2022 and Forecast 2023–2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Drug Types
15.3.3. By Types
15.3.4. By Disease Indication
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Types
15.4.3. By Types
15.4.4. By Disease Indication
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug Types
15.8.1.2.2. By Types
15.8.1.2.3. By Disease Indication
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug Types
15.8.2.2.2. By Types
15.8.2.2.3. By Disease Indication
15.8.2.2.4. By Distribution Channel
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug Types
15.8.3.2.2. By Types
15.8.3.2.3. By Disease Indication
15.8.3.2.4. By Distribution Channel
15.8.4. U.K. Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug Types
15.8.4.2.2. By Types
15.8.4.2.3. By Disease Indication
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug Types
15.8.5.2.2. By Types
15.8.5.2.3. By Disease Indication
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug Types
15.8.6.2.2. By Types
15.8.6.2.3. By Disease Indication
15.8.6.2.4. By Distribution Channel
15.8.7. Nordic Countries Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug Types
15.8.7.2.2. By Types
15.8.7.2.3. By Disease Indication
15.8.7.2.4. By Distribution Channel
15.8.8. Russia Market Analysis
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Drug Types
15.8.8.2.2. By Types
15.8.8.2.3. By Disease Indication
15.8.8.2.4. By Distribution Channel
16. East Asia Market Analysis 2012–2022 and Forecast 2023–2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug Types
16.3.3. By Types
16.3.4. By Disease Indication
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Types
16.4.3. By Types
16.4.4. By Disease Indication
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug Types
16.8.1.2.2. By Types
16.8.1.2.3. By Disease Indication
16.8.1.2.4. By Distribution Channel
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug Types
16.8.2.2.2. By Types
16.8.2.2.3. By Disease Indication
16.8.2.2.4. By Distribution Channel
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug Types
16.8.3.2.2. By Types
16.8.3.2.3. By Disease Indication
16.8.3.2.4. By Distribution Channel
17. South Asia Market Analysis 2012–2022 and Forecast 2023–2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Drug Types
17.3.3. By Types
17.3.4. By Disease Indication
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Types
17.4.3. By Types
17.4.4. By Disease Indication
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug Types
17.8.1.2.2. By Types
17.8.1.2.3. By Disease Indication
17.8.1.2.4. By Distribution Channel
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug Types
17.8.2.2.2. By Types
17.8.2.2.3. By Disease Indication
17.8.2.2.4. By Distribution Channel
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug Types
17.8.3.2.2. By Types
17.8.3.2.3. By Disease Indication
17.8.3.2.4. By Distribution Channel
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug Types
17.8.4.2.2. By Types
17.8.4.2.3. By Disease Indication
17.8.4.2.4. By Distribution Channel
18. Oceania Market 2012-2022 and Forecast 2023-2033
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug Types
18.3.3. By Types
18.3.4. By Disease Indication
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Types
18.4.3. By Types
18.4.4. By Disease Indication
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug Types
18.8.1.2.2. By Types
18.8.1.2.3. By Disease Indication
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug Types
18.8.2.2.2. By Types
18.8.2.2.3. By Disease Indication
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2012–2022 and Forecast 2023–2033
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug Types
19.3.3. By Types
19.3.4. By Disease Indication
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Types
19.4.3. By Types
19.4.4. By Disease Indication
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug Types
19.8.1.2.2. By Types
19.8.1.2.3. By Disease Indication
19.8.1.2.4. By Distribution Channel
19.8.2. Türkiye Anti-VEGF Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug Types
19.8.2.2.2. By Types
19.8.2.2.3. By Disease Indication
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug Types
19.8.3.2.2. By Types
19.8.3.2.3. By Disease Indication
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug Types
19.8.4.2.2. By Types
19.8.4.2.3. By Disease Indication
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. Regional Footprint Analysis
20.4.2. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financial
21.3.1.5. Key Developments
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.1.7.1. Marketing Strategies
21.3.1.7.2. Channel Strategies
21.3.2. Bayer AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financial
21.3.2.5. Key Developments
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.2.7.1. Marketing Strategies
21.3.2.7.2. Channel Strategies
21.3.3. Novartis AG
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financial
21.3.3.5. Key Developments
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.3.7.1. Marketing Strategies
21.3.3.7.2. Channel Strategies
21.3.4. Sanofi SA
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financial
21.3.4.5. Key Developments
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.4.7.1. Marketing Strategies
21.3.4.7.2. Channel Strategies
21.3.5. Exelixis Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financial
21.3.5.5. Key Developments
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.5.7.1. Marketing Strategies
21.3.5.7.2. Channel Strategies
21.3.6. Eisai Co. Ltd.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financial
21.3.6.5. Key Developments
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.6.7.1. Marketing Strategies
21.3.6.7.2. Channel Strategies
21.3.7. Amgen Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financial
21.3.7.5. Key Developments
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.7.7.1. Marketing Strategies
21.3.7.7.2. Channel Strategies
21.3.8. F. Hoffmann-La Roche Ltd.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financial
21.3.8.5. Key Developments
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.8.7.1. Marketing Strategies
21.3.8.7.2. Channel Strategies
21.3.9. Eli Lilly and Company
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financial
21.3.9.5. Key Developments
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.9.7.1. Marketing Strategies
21.3.9.7.2. Channel Strategies
21.3.10. Amneal Pharmaceuticals Inc.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Key Financial
21.3.10.5. Key Developments
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.10.7.1. Marketing Strategies
21.3.10.7.2. Channel Strategies
21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Sales Footprint
21.3.11.4. Key Financial
21.3.11.5. Key Developments
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
21.3.11.7.1. Marketing Strategies
21.3.11.7.2. Channel Strategies
21.3.12. Takeda Pharmaceutical Co. Ltd.
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Sales Footprint
21.3.12.4. Key Financial
21.3.12.5. Key Developments
21.3.12.6. SWOT Analysis
21.3.12.7. Strategy Overview
21.3.12.7.1. Marketing Strategies
21.3.12.7.2. Channel Strategies
21.3.13. Sino Biopharma
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Sales Footprint
21.3.13.4. Key Financial
21.3.13.5. Key Developments
21.3.13.6. SWOT Analysis
21.3.13.7. Strategy Overview
21.3.13.7.1. Marketing Strategies
21.3.13.7.2. Channel Strategies
21.3.14. HUTCHMED
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Sales Footprint
21.3.14.4. Key Financial
21.3.14.5. Key Developments
21.3.14.6. SWOT Analysis
21.3.14.7. Strategy Overview
21.3.14.7.1. Marketing Strategies
21.3.14.7.2. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 02: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 03: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 04: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 05: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 06: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 07: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 08: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 09: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 10: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 11: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Region
Table 12: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Region
Table 13: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 14: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 15: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 16: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 17: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 18: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 19: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 20: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 21: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 22: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 23: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 24: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 25: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 26: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 27: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 28: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 29: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 30: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 31: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 32: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 33: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 34: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 35: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 36: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 37: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 38: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 39: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 40: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 41: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 42: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 43: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 44: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 45: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 46: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 47: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 48: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 49: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 50: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 51: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 52: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 53: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 54: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 55: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 56: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 57: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 58: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 59: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 60: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 61: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 62: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 63: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 64: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 65: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 66: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 67: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 68: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 69: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 70: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 71: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 72: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 73: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 74: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 75: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 76: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 77: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 78: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 79: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 80: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 81: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 82: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 83: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 84: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 85: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 86: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 87: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 88: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 89: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 90: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 91: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 92: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 93: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 94: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 95: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 96: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Anti-VEGF Market Value, 2012-2022
Figure 02: Global Anti-VEGF Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2032
Figure 03: Global Anti-VEGF Market Absolute $ Opportunity, 2022–2032
Figure 04: Global Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2032
Figure 05: Global Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 06: Global Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2032
Figure 07: Global Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 08: Global Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2032
Figure 09: Global Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 10: Global Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 11: Global Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2032
Figure 12: Global Anti-VEGF Market Share Analysis (%) by Region, 2022 & 2032
Figure 13: Global Anti-VEGF Market Attractiveness Analysis, By Region, 2023-2033
Figure 14: North America Anti-VEGF Market Value Share, By Country (2023 E)
Figure 15: North America Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 16: North America Anti-VEGF Market Value Share, By Types (2023 E)
Figure 17: North America Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 18: North America Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 19: North America Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 20: North America Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 21: North America Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 22: North America Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 23: North America Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 24: North America Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 25: North America Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 26: U.S. Market Value Proportion Analysis, 2022
Figure 27: U.S. Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 28: U.S. Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 29: U.S. Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 30: U.S. Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 31: Canada Market Value Proportion Analysis, 2022
Figure 32: Canada Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 33: Canada Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 34: Canada Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 35: Canada Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 36: Latin America Anti-VEGF Market Value Share, By Country (2023 E)
Figure 37: Latin America Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 38: Latin America Anti-VEGF Market Value Share, By Types (2023 E)
Figure 39: Latin America Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 40: Latin America Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 41: Latin America Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 42: Latin America Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 43: Latin America Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 44: Latin America Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 45: Latin America Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 46: Latin America Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 47: Latin America Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 48: Brazil Market Value Proportion Analysis, 2022
Figure 49: Brazil Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 50: Brazil Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 51: Brazil Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 52: Brazil Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 53: Mexico Market Value Proportion Analysis, 2022
Figure 54: Mexico Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 55: Mexico Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 56: Mexico Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 57: Mexico Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 58: Argentina Market Value Proportion Analysis, 2022
Figure 59: Argentina Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 60: Argentina Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 61: Argentina Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 62: Argentina Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 63: Europe Anti-VEGF Market Value Share, By Country (2023 E)
Figure 64: Europe Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 65: Europe Anti-VEGF Market Value Share, By Types (2023 E)
Figure 66: Europe Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 67: Europe Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 68: Europe Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 69: Europe Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 70: Europe Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 71: Europe Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 72: Europe Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 73: Europe Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 74: Europe Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 75: Germany Market Value Proportion Analysis, 2022
Figure 76: Germany Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 77: Germany Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 78: Germany Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 79: Germany Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 80: U.K. Market Value Proportion Analysis, 2022
Figure 81: U.K. Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 82: U.K. Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 83: U.K. Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 84: U.K. Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 85: Italy Market Value Proportion Analysis, 2022
Figure 86: Italy Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 87: Italy Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 88: Italy Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 89: Italy Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 90: France Market Value Proportion Analysis, 2022
Figure 91: France Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 92: France Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 93: France Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 94: France Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 95: Spain Market Value Proportion Analysis, 2022
Figure 96: Spain Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 97: Spain Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 98: Spain Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 99: Spain Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 100: Russia Market Value Proportion Analysis, 2022
Figure 101: Russia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 102: Russia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 103: Russia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 104: Russia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 105: Nordic Countries Market Value Proportion Analysis, 2022
Figure 106: Nordic Countries Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 107: Nordic Countries Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 108: Nordic Countries Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 109: Nordic Countries Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 110: BENULUX Market Value Proportion Analysis, 2022
Figure 111: BENULUX Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 112: BENULUX Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 113: BENULUX Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 114: BENULUX Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 115: East Asia Anti-VEGF Market Value Share, By Country (2023 E)
Figure 116: East Asia Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 117: East Asia Anti-VEGF Market Value Share, By Types (2023 E)
Figure 118: East Asia Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 119: East Asia Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 120: East Asia Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 121: East Asia Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 122: East Asia Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 123: East Asia Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 124: East Asia Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 125: East Asia Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 126: East Asia Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 127: China Market Value Proportion Analysis, 2022
Figure 128: China Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 129: China Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 130: China Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 131: China Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 132: Japan Market Value Proportion Analysis, 2022
Figure 133: Japan Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 134: Japan Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 135: Japan Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 136: Japan Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 137: South Korea Market Value Proportion Analysis, 2022
Figure 138: South Korea Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 139: South Korea Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 140: South Korea Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 141: South Korea Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 142: South Asia Anti-VEGF Market Value Share, By Country (2023 E)
Figure 143: South Asia Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 144: South Asia Anti-VEGF Market Value Share, By Types (2023 E)
Figure 145: South Asia Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 146: South Asia Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 147: South Asia Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 148: South Asia Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 149: South Asia Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 150: South Asia Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 151: South Asia Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 152: South Asia Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 153: South Asia Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 154: India Market Value Proportion Analysis, 2022
Figure 155: India Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 156: India Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 157: India Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 158: India Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 159: Thailand Market Value Proportion Analysis, 2022
Figure 160: Thailand Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 161: Thailand Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 162: Thailand Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 163: Thailand Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 164: Indonesia Market Value Proportion Analysis, 2022
Figure 165: Indonesia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 166: Indonesia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 167: Indonesia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 168: Indonesia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 169: Malaysia Market Value Proportion Analysis, 2022
Figure 170: Malaysia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 171: Malaysia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 172: Malaysia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 173: Malaysia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 174: Oceania Anti-VEGF Market Value Share, By Country (2023 E)
Figure 175: Oceania Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 176: Oceania Anti-VEGF Market Value Share, By Types (2023 E)
Figure 177: Oceania Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 178: Oceania Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 179: Oceania Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 180: Oceania Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 181: Oceania Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 182: Oceania Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 183: Oceania Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 184: Oceania Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 185: Oceania Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 186: Australia Market Value Proportion Analysis, 2022
Figure 187: Australia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 188: Australia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 189: Australia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 190: Australia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 191: New Zealand Market Value Proportion Analysis, 2022
Figure 192: New Zealand Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 193: New Zealand Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 194: New Zealand Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 195: New Zealand Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 196: Middle East & Africa Anti-VEGF Market Value Share, By Country (2023 E)
Figure 197: Middle East & Africa Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 198: Middle East & Africa Anti-VEGF Market Value Share, By Types (2023 E)
Figure 199: Middle East & Africa Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 200: Middle East & Africa Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 201: Middle East & Africa Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 202: Middle East & Africa Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 203: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 204: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 205: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 206: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 207: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 208: GCC Countries Market Value Proportion Analysis, 2022
Figure 209: GCC Countries Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 210: GCC Countries Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 211: GCC Countries Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 212: GCC Countries Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 213: Türkiye Market Value Proportion Analysis, 2022
Figure 214: Türkiye Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 215: Türkiye Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 216: Türkiye Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 217: Türkiye Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 218: North Africa Market Value Proportion Analysis, 2022
Figure 219: North Africa Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 220: North Africa Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 221: North Africa Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 222: North Africa Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 223: South Africa Market Value Proportion Analysis, 2022
Figure 224: South Africa Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 225: South Africa Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 226: South Africa Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 227: South Africa Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
